Pancreatic ductal adenocarcinoma, the most prevalent form of pancreatic cancer, is currently the fourth leading cause of death in the United States. It is projected to become the second leading cause of death within the next decade due to its poor prognosis and rising incidence. FOLFIRINOX or gemcitabine plus nab-paclitaxel are recommended as the first-line treatments for this aggressive cancer.
The company we are profiling today is Lisata Therapeutics Inc. (LSTA), which is developing a drug for patients with metastatic pancreatic ductal adenocarcinoma.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com